Anti-Human TREM2 Polyclonal Antibody (HV166014)

Name: Anti-Human TREM2 Polyclonal Antibody
Brand: abinScience
SKU: HV166014
Price: 96 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HV166014

Species reactivity

Human

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human TREM2 (His19-Arg161).

Target

Triggering receptor expressed on myeloid cells 2, Triggering receptor expressed on monocytes 2, TREM-2, TREM2

Purification

Purified by antigen affinity column.

Accession

Q9NZC2

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Triggering receptor expressed on myeloid cells 2 (TREM2) is a ~25 kDa protein. Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia. Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, and the anti-inflammatory cytokine ARG1. Acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia. Binds phospholipids (preferably anionic lipids) such as phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin. TREM2 is the therapeutic target of AL002 (clinical).

1. Bouchon, A. et al. (2000) Journal of immunology (Baltimore, Md. : 1950) 164, 4991-5. PMID: 10799849

2. Yeh, FL. et al. (2016) Neuron 91, 328-40. PMID: 27477018

3. Zhao, Y. et al. (2018) Neuron 97, 1023-1031.e7. PMID: 29518356

4. Sudom, A. et al. (2018) The Journal of biological chemistry 293, 12634-12646. PMID: 29794134

5. Kleinberger, G. et al. (2014) Science translational medicine 6, 243ra86. PMID: 24990881

6. Filipello, F. et al. (2018) Immunity 48, 979-991.e8. PMID: 29752066

7. Bouchon, A. et al. (2001) The Journal of experimental medicine 194, 1111-22. PMID: 11602640

8. Paloneva, J. et al. (2003) The Journal of experimental medicine 198, 669-75. PMID: 12925681

Note

For research use only.

Images

Western blot

Western blot analysis was performed using anti-TREM2 polyclonal antibody at 1ug/mL on various samples.
Lane 1: RAW264.7 cell lysate
Lane 2: Jurkat cell lysate
Lane 3: THP-1 cell lysate
Lane 4: HL-60 cell lysate